Loading…
Gyre Therapeutics, Inc. is projected to rise to $6.31 by 2027, a +7% move from its current price of $5.92. GYRE is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $5.74 | $5.92 | $6.11 | +0.05% |
| May 30 | $5.67 | $5.93 | $6.19 | +0.09% |
| May 31 | $5.62 | $5.93 | $6.25 | +0.14% |
| Jun 1 | $5.58 | $5.93 | $6.31 | +0.18% |
| Jun 2 | $5.54 | $5.93 | $6.35 | +0.23% |
| Jun 3 | $5.51 | $5.94 | $6.40 | +0.27% |
| Jun 4 | $5.48 | $5.94 | $6.44 | +0.32% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $5.48 | $5.94 | $6.44 | +0.32% |
| Week 2 | $5.31 | $5.96 | $6.68 | +0.64% |
| Week 3 | $5.19 | $5.98 | $6.88 | +0.96% |
| Week 4 | $5.10 | $6.00 | $7.05 | +1.28% |
| Week 5 | $5.02 | $6.02 | $7.21 | +1.61% |
| Week 6 | $4.95 | $6.03 | $7.36 | +1.93% |
| Week 7 | $4.88 | $6.05 | $7.50 | +2.26% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Gyre Therapeutics, Inc. is a pharmaceutical company focused on the development and commercialization of small-molecule, anti-inflammatory, and anti-fibrotic drugs targeting organ fibrosis. It offers ETUARY (Pirfenidone), an anti-fibrotic therapy approved for idiopathic pulmonary fibrosis, and it has multiple Phase 3 programs including F351 (Hydronidone) for CHB-associated liver fibrosis; it has completed Phase 1 trials for liver fibrosis associated with metabolic dysfunction-associated steatohepatitis and has a Phase 2 program for F573 targeting acute liver failure.
The company also advances preclinical products including F230 for pulmonary arterial hypertension and F528 for chronic obstructive pulmonary disease. Gyre Therapeutics, Inc. was founded in 2002 and is headquartered in San Diego, California.
It operates as a subsidiary of GNI USA, Inc.
Gyre Therapeutics, Inc. trades in the Healthcare sector with a current price of $6.06 and a market capitalization of $587.99M. It is ranked 2920 by market cap among listed assets. The stock’s current price and market position reflect a modest entry in the market today.
A major floor 24.5% below — a decisive break under it would weaken the trend.
Price is testing support right now (0.0% away) — a key level to hold.
The nearest ceiling, 36.8% above — a clean break opens room to run.
A major ceiling 49.1% above — clearing it would confirm fresh momentum.
Key GYRE support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of GYRE market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $6.03 | Sell | $6.07 | Sell |
| MA 10 | $6.37 | Sell | $6.34 | Sell |
| MA 20 | $6.96 | Sell | $6.73 | Sell |
| MA 50 | $7.19 | Sell | $7.16 | Sell |
| MA 100 | $7.57 | Sell | $7.42 | Sell |
| MA 200 | $7.64 | Sell | $7.83 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 31.51 | Neutral |
| Stoch RSI (14) | 0.67 | Buy |
| CCI (20) | -110.28 | Sell |
| Williams %R (14) | -100.00 | Info |
| MACD (12,26,9) | -0.13 | Sell |
| ROC (12) | -20.75 | Sell |
| Bollinger %B (20,2) | 0.13 | Neutral |
| Stochastic %K (14) | 0.00 | Buy |
| TRIX (15) | -0.55 | Sell |
| Awesome (5,34) | -1.24 | Sell |
| Ultimate (7,14,28) | 19.50 | Buy |
| Momentum (10) | -1.38 | Sell |
| Aroon Osc (25) | -56.00 | Sell |
| Hull MA (9) | 5.86 | Buy |
| ADX (14) | 21.28 | Sell |
| ATR (14) | 0.20 | Info |
The 30-day technical picture shows a price range from $4.90 to $7.50, with RSI14 at 30, indicating bearish momentum. The price sits below both the 50-day and 200-day moving averages, which are $7.26 and $7.66 respectively. Support is at $6.04 and resistance at $8.10, suggesting limited downside yet meaningful upside above the near-term hurdle levels.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $5.92 | $5.92 | $7.80 | 0% | Neutral | |
| $4.94 | $6.31 | $8.56 | +7% | Neutral | |
| $5.17 | $6.81 | $9.61 | +15% | Neutral | |
| $4.98 | $6.72 | $9.79 | +14% | Neutral | |
| $5.97 | $8.25 | $12.34 | +39% | Bullish | |
| $7.09 | $10.01 | $15.31 | +69% | Bullish | |
| $6.78 | $9.77 | $15.25 | +65% | Bullish | |
| $7.02 | $10.30 | $16.37 | +74% | Bullish | |
| $7.00 | $10.45 | $16.91 | +77% | Bullish | |
| $6.68 | $10.15 | $16.69 | +72% | Bullish | |
| $9.74 | $15.99 | $28.10 | +170% | Bullish | |
| $13.99 | $26.34 | $50.96 | +345% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $5.92 | $5.92 | $6.97 | +0.00% |
| June 2026 | $5.20 | $6.13 | $7.40 | +3.49% |
| July 2026 | $5.19 | $6.17 | $7.56 | +0.72% |
| August 2026 | $4.98 | $5.97 | $7.40 | -3.28% |
| September 2026 | $4.97 | $5.98 | $7.49 | +0.27% |
| October 2026 | $5.09 | $6.17 | $7.79 | +3.16% |
| November 2026 | $5.04 | $6.13 | $7.80 | -0.63% |
| December 2026 | $4.98 | $6.09 | $7.80 | -0.75% |
Click any year to see its month-by-month GYRE forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Gyre Therapeutics, Inc.'s 2026 outlook centres on $5.92, within a $5.92 to $7.80 range. That marks a 0% change versus current levels. Price action looks broadly range-bound.
By 2027, GYRE could reach as high as $8.56, with a base case around $6.31 and support toward $4.94 — roughly +7% from $5.92. A consolidation phase looks the most probable path here.
Expect GYRE to range from $5.17 to $9.61 through 2028. The $6.81 average target implies a +15% move from current prices. That is up +8% on the projected 2027 average. Price action looks broadly range-bound.
The GYRE price prediction for 2029 points to an average of $6.72 (low $4.98, high $9.79) — a potential gain of +14% on today's $5.92. A consolidation phase looks the most probable path here.
In 2030, GYRE is projected to trade between $5.97 and $12.34, averaging $8.25 — a potential gain of +39% from today's $5.92. That is up +23% on the projected 2029 average. Momentum favours further upside here.
Gyre Therapeutics, Inc.'s 2031 outlook centres on $10.01, within a $7.09 to $15.31 range. That is up +21% on the projected 2030 average. That marks a +69% change versus current levels. Buyers look set to stay in control over this stretch.
By 2032, GYRE could reach as high as $15.25, with a base case around $9.77 and support toward $6.78 — roughly +65% from $5.92. Momentum favours further upside here.
Expect GYRE to range from $7.02 to $16.37 through 2033. The $10.30 average target implies a +74% move from current prices. That is up +5% on the projected 2032 average. Buyers look set to stay in control over this stretch.
The GYRE price prediction for 2034 points to an average of $10.45 (low $7.00, high $16.91) — a potential gain of +77% on today's $5.92. Momentum favours further upside here.
In 2035, GYRE is projected to trade between $6.68 and $16.69, averaging $10.15 — a potential gain of +72% from today's $5.92. That is -3% versus the projected 2034 average. Buyers look set to stay in control over this stretch.
Gyre Therapeutics, Inc.'s 2040 outlook centres on $15.99, within a $9.74 to $28.10 range. That is up +58% on the projected 2035 average. That marks a +170% change versus current levels. Momentum favours further upside here.
By 2050, GYRE could reach as high as $50.96, with a base case around $26.34 and support toward $13.99 — roughly +345% from $5.92. Buyers look set to stay in control over this stretch.
Investing $1,000 in GYRE today (≈ 168.918919 GYRE) could be worth
$4,449.45
+$3,449.45 (+345%) by 2050 · US Dollar
Based on the average projected GYRE price of $26.34 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in GYREwould be worth at today's price.
$1,000 invested in GYRE on May 27, 2025 (≈ 98.231824 GYRE) would be worth
$581.53
-$418.47 (-41.8%) today · 0.58× · US Dollar
Based on a GYRE entry price of $10.18 vs. today's $5.92.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $6.04 | $980.13 | -2.0% |
| 1 month ago | $7.63 | $775.88 | -22.4% |
| 3 months ago | $8.52 | $694.84 | -30.5% |
| 6 months ago | $7.75 | $763.87 | -23.6% |
| 1 year ago | $10.18 | $581.53 | -41.8% |
| All time (5.0y) ago | $65.1 | $90.94 | -90.9% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our GYRE forecast.
Our base-case forecast reaches $12.00 around 2040.
Implied market cap at $12.00: $1.16B
The multi-year forecast presents a trajectory from neutral in the near term toward bullish in the long term. For 2026–2029 the averages are around $6.06–$6.85, with limited upside and neutral sentiment. Beginning in 2030 the forecast turns bullish, with an average of $8.50 and a potential range from $6.08 to $12.86, yielding an estimated ROI of 40.2%.
By 2040 the average is projected at $16.23 (min $9.65, max $29.04) with an ROI of 167.8% and bullish sentiment. In 2050 the average is $26.96 (min $13.81, max $53.30), with an ROI of 344.8% and bullish sentiment. These figures are estimates and not guarantees, and actual results can vary with market conditions and company developments.
Tap a question to reveal the answer.
The forecast shows an average price of $8.50, with a min of $6.08 and a max of $12.86, and an ROI of 40.2%. The sentiment for 2030 is BULLISH.
The forecast indicates a shift to bullish sentiment from 2030 onward, with 2040 averaging $16.23 (ROI 167.8%) and 2050 averaging $26.96 (ROI 344.8%), suggesting strong long-term upside but with uncertainty and no guarantees.
Yes. The 2030 forecast lists a max of $12.86, with an average of $8.50 and a min of $6.08, corresponding to a 40.2% ROI.
Current price is $6.06 and market cap is $587.99M.
The 30-day range is $4.90 to $7.50, with RSI14 at 30 and sentiment BEARISH. The stock trades below the 50-day SMA of $7.26 and the 200-day SMA of $7.66, with near-term support at $6.04 and resistance at $8.10.
Gyre Therapeutics, Inc. Community Discussion
0Share your Gyre Therapeutics, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.